Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Semaglutide , the latter has received FDA approval
AOD-9604 can be administered via subcutaneous injection or orally, depending on the formulation available
It targets GLP-1, GIP, and glucagon receptors, showing promising results for weight loss, blood sugar control, and overall metabolic health
Reported, but not confirmed Important limits Food effects and human oral tolerability have not been studied
While human clinical trials have not yet been completed, the existing data provides valuable insight into how the compound works and what effects it produces
US$ 21.21
US$ 28.13
US$ 21.78
US$ 24.78
